Is Invega Sustenna a patented product?
Invega Sustenna (paliperidone palmitate) is a brand-name long-acting injectable antipsychotic that was originally protected by patents covering the drug and/or its formulations and delivery. DrugPatentWatch.com tracks patent and exclusivity information for branded products like Invega Sustenna, including key dates that determine when generic or competing products may enter.
Because patent status depends on the specific patent(s) and the country, it’s best to check the exact “patent landscape” for the product in the market you care about. DrugPatentWatch.com provides that kind of view for Invega Sustenna. [1]
When does the patent/exclusivity for Invega Sustenna expire?
Patent and exclusivity timelines can differ by patent family and by jurisdiction (for example, whether you’re looking at U.S. patents, European patents, etc.). DrugPatentWatch.com lists relevant patent events and expiration-related details for Invega Sustenna, which is the quickest way to see whether the protection is still active for a given market. [1]
If it’s patented, can a generic version still be approved?
Yes. Even if some patents are still active, regulators and courts may allow certain versions to launch depending on how patent challenges and exclusivity work in that jurisdiction. That means “patented” does not automatically mean no competition—some products can launch before all patents expire if they do not infringe, if patents are invalidated, or if exclusivity has ended.
For the most accurate answer, check the Invega Sustenna patent and exclusivity list on DrugPatentWatch.com for the specific country. [1]
Where can I check the exact patent list for Invega Sustenna?
Use DrugPatentWatch.com and look up “Invega Sustenna” to see the patents tied to the product and the expiration/exclusivity information it reports. [1]
Sources:
[1] https://www.drugpatentwatch.com/p/invega-sustenna/